Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

FGEN FibroGen Inc

1,10

0,00 (0,00%)

11 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Traders Rush To Buy Biotech Following Q1 Earnings Beat

A California-based biotech company is stealing the show so far during Tuesday’s session after the company reported Q1 2024 earnings after yesterday’s market...

To read the full story on AllPennyStocks.com, click here.

FibroGen (NASDAQ:FGEN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more FibroGen Charts.

FibroGen (NASDAQ:FGEN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more FibroGen Charts.

News FibroGen Inc

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 11 Juni 2024 (6 Stunden vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 8 Juni 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Samstag 8 Juni 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Freitag 7 Juni 2024 (3 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (4 Tage vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Freitag 7 Juni 2024 (4 Tage vor) • Edgar (US Regulatory)

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
Montag 3 Juni 2024 (1 Woche vor) • GlobeNewswire Inc.

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
Montag 3 Juni 2024 (1 Woche vor) • GlobeNewswire Inc.

Weitere FibroGen Inc News-Artikel

Health Care Select Sector

JP Morgan Chase

Invesco QQQ Trust Series 1

Deutsche Lufthansa

Gold vs US Dollar

Energy Select Sector SPDR

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen